- Home
- NRIM vs OMER Comparison
NRIM vs OMER Comparison
Compare NRIM & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- OMER
- Stock Information
- Founded
- NRIM 1990
- OMER 1994
- Country
- NRIM United States
- OMER United States
- Employees
- NRIM N/A
- OMER N/A
- Industry
- NRIM Savings Institutions
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- OMER Health Care
- Exchange
- NRIM Nasdaq
- OMER Nasdaq
- Market Cap
- NRIM 444.5M
- OMER 513.8M
- IPO Year
- NRIM N/A
- OMER 2009
- Fundamental
- Price
- NRIM $22.14
- OMER $7.17
- Analyst Decision
- NRIM
- OMER Strong Buy
- Analyst Count
- NRIM 0
- OMER 6
- Target Price
- NRIM N/A
- OMER $27.50
- AVG Volume (30 Days)
- NRIM 104.5K
- OMER 8.3M
- Earning Date
- NRIM 10-22-2025
- OMER 11-07-2025
- Dividend Yield
- NRIM 2.89%
- OMER N/A
- EPS Growth
- NRIM 91.08
- OMER N/A
- EPS
- NRIM 2.80
- OMER N/A
- Revenue
- NRIM $201,544,000.00
- OMER N/A
- Revenue This Year
- NRIM $11.35
- OMER N/A
- Revenue Next Year
- NRIM $7.32
- OMER N/A
- P/E Ratio
- NRIM $7.89
- OMER N/A
- Revenue Growth
- NRIM 42.34
- OMER N/A
- 52 Week Low
- NRIM $15.92
- OMER $2.95
- 52 Week High
- NRIM $25.05
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- NRIM 26.01
- OMER 55.84
- Support Level
- NRIM $21.68
- OMER $7.44
- Resistance Level
- NRIM $23.12
- OMER $8.05
- Average True Range (ATR)
- NRIM 0.69
- OMER 0.77
- MACD
- NRIM 2.22
- OMER -0.12
- Stochastic Oscillator
- NRIM 72.26
- OMER 1.99
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.